Keywords: devgen, sees, good, data, trials, oral, tnf

Devgen sees good data in trials of oral TNF inhibitors

Article | 28 August 2006

Print This

Belgian biotechnology firm Devgen says that preclinical trials of a series of compounds, that inhibit tumor necrosis factor alpha, have ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in